The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD. This ...

New draft guidance from the FDA is urging pharma companies to accelerate efforts to transition from animal testing to ...

As geopolitical tensions ratchet up around the world, the European Psychiatric Association (EPA) has launched an initiative ...

Novo Nordisk is facing generics of its GLP-1 drug in India, Atrogi is testing a new weight loss approach, and there's new data on Structure's lead drug. Indian patent on semagluti ...

Recognized as the field’s most comprehensive end‑to‑end meeting, this summit brings together discovery, engineering, translational, and clinical development experts to push the boundaries of TCE ...

Eli Lilly has positive phase 3 results for its triple agonist retatrutide in type 2 diabetes (T2D) to go with its earlier encouraging data as a weight-loss therapy.

The US regulator confirmed approval of IBAT inhibitor linerixibat, under the Lynavoy trade name, as a treatment for cholestatic pruritus in PBC on 17th March. PBC is a chronic, progressive autoimmune ...

According to the latest statistics, brain tumours are still the biggest cancer killer of children and young adults under 40 in the UK. According to the latest data, more than 5,400 people lose their ...

Johnson & Johnson's much-anticipated oral IL-23 inhibitor, icotrokinra, has claimed FDA approval as a first-line treatment for plaque psoriasis.

Basecamp Research has launched a new scientific initiative, called the Trillion Gene Atlas, to bring together genomic data ...

The aligned pathway for UK drugs regulator MHRA and reimbursement authority NICE – aimed at slashing the time it takes for ...

An appeals court in the US has said that AbbVie, AstraZeneca, Novartis, and Sanofi will have to defend claims they defrauded ...